论文部分内容阅读
目的观察前列腺癌患者完全性雄激素阻断治疗出现血清前列腺特异性抗原(PSA)升高后,停用氟他胺后PSA的变化。方法78例前列腺癌患者,全雄阻断治疗PSA正常后若再次PSA>4ng/ml,则停服氟他胺至少连续3月,观察PSA的变化情况。结果(1)停服氟他胺后有42例PSA下降超过50%以上;(2)42例PSA下降超过50%以上者,19例停药后3月内达到,23例6月内达到;(3)23/42例停药6月内维持PSA<4ng/ml,14/42例停药12月内维持PSA<4ng/ml,5/42例维持12月以上;(4)42例患者中停药后PSA再次升高超过4ng/ml者,再次服用氟他胺后,9例PSA出现下降表现。结论前列腺癌患者在手术去势和氟他胺联合治疗后出现PSA上升者,在改用二线治疗前可先停用氟他胺。
Objective To investigate the changes of PSA after the debridement of flutamide after complete prostatectomy (PSA) in patients with prostate cancer. Methods 78 cases of prostate cancer patients, all-male block treatment PSA normal again if PSA> 4ng / ml, then stop taking flutamide at least for 3 months to observe the changes of PSA. Results (1) 42 cases of PSA decreased more than 50% after stopping taking flutamide; (2) 42 cases of PSA decreased more than 50%, 19 cases achieved within 3 months after stopping drug and 23 cases reached within 6 months; (3) 23/42 patients discontinued maintenance of PSA <4ng / ml in 6 months, 14/42 patients discontinued maintenance of PSA <4ng / ml in 12 months, 5/42 cases maintained for more than 12 months; (4) 42 patients In the withdrawal of PSA once again increased more than 4ng / ml who, after taking flutamide again, 9 cases of PSA decreased performance. Conclusions Prostate cancer patients with elevated PSA after surgical castration and flutamide combination therapy may discontinue flutamide prior to switching to second-line therapy.